IntraLinks announced IntraLinks for Study Management, a secure, online platform for managing and monitoring all communication and activity with investigative sites and other outside parties during clinical trials from study start-up through study close-out. The new offering expands the full suite of IntraLinks’ solutions for clinical operations, which accelerates business processes, cuts costs, and reduces risks throughout the clinical trial lifecycle.
IntraLinks for Study Management specifically helps to:
· Centralize all study-related documents, communication and activity history in an organized, consistent, and searchable fashion
· Standardize and automate processes such as contract & budget negotiation, regulatory document distribution and collection and ongoing document exchange
· Eliminate repetitive and redundant site data entry and document submission
· Provide sites with a personalized view of tasks, requests and due dates, with reminder alerts and a secure communication channel to ensure timely site activation
· Monitor process progress with real-time activity dashboards and meet regulatory compliance with detailed access reports and audit trails
IntraLinks also offers a collaborative platform for site recruitment and safety reporting as part of its suite of solutions. IntraLinks for Site Recruitment enables users to eliminate the redundancy and manual tasks related to feasibility survey creation, distribution and collection. IntraLinks for Safety Document Exchange provides a secure environment where safety teams can receive notifications, route them for review, and instantaneously distribute subsequent letters to all parties requiring notification in an intelligent, automated, and auditable fashion.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.